Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEAP-001 first-line pembrolizumab + lenvatinib versus carboplatin + paclitaxel in advanced or recurrent endometrial carcinoma
MOH_2019-08-29_007370Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jul 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab and lenvatinib in endometrial cancer (EC) (2 arms), sponsored by Merck & Co. Started Jul 2019; status: active, not recruiting.
02
Drugs
pembrolizumablenvatinib
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on MOH_2019-08-29_007370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-08-29_007370.